Navigation Links
New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

ectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (ECOG 5203)

Findings from this single-arm Phase 2 study provide encouraging data for the potential use of Nexavar in combination with docetaxel and cisplatin to treat patients with metastatic/advanced gastric/GEJ adenocarcinoma. The most common treatment-emergent adverse events included neutropenia, fatigue, anorexia, hand-foot reaction, nausea, diarrhea and dehydration.

The lead investigator for this study is Weijing Sun, MD, assistant professor of medicine, University of Pennsylvania, director of the Upper GI and Pancreatic-Biliary-Hepatic Cancer Group and the associate director of the GI Cancer Program. (abstract #4535).

Ovarian

Phase 2 Trial of Sorafenib in Persistent or Recurrent Epithelial Ovarian Cancer or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

Preliminary findings from this Phase 2 study suggest that Nexavar is active and tolerated in patients with recurrent epithelial ovarian cancer. The most common treatment-emergent adverse events were dermatologic and metabolic.

The lead investigator for this study is Daniela Matei, M.D., Ph.D., assistant professor, department of medicine, Walther Oncology Center, Indiana University, Bloomington, IN. (abstract #5537).

"We continue to be encouraged by Nexavar's potential activity as a single agent or in combination with other chemotherapeutic agents in these early stage clinical trials in tumor types with high unmet treatment needs," said Susan Kelley, MD, vice president, Therapeutic Area Oncology, Bayer HealthCare Pharmaceuticals. "The more data we compile from various studies in multiple tumor types, the better informed we are to determine the appropriate direction for further development of Nexavar in additional clinical cancer settings."

Nexavar's Differentiated Mechanism

Nexavar targets both the tumor cell and tumor vasculature. In preclinical studies, Nexavar has be
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
2. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
3. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
10. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/6mlrvg/an_introduction ) has ... to Medical Device Software: Regulations and Requirements (London, ... their offering. This course will ... requirements that apply to Medical Device Software. The ... examples and state-of- the-art practices identified from Notified ...
(Date:9/2/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/r6wspz/drug_delivery_in ) has ... "Drug Delivery in Central Nervous System Diseases ... offering. Advances in understanding of ... new avenues and possibilities for improved drug delivery ... enzymes, and receptors that control the penetration of ...
(Date:9/2/2015)... BOCA RATON, Fla. , Sept. 2, 2015 ... Cartledge , MD, FACS, has begun performing ultra-minimally ... patients who are on anticoagulants such as Coumadin, ... of Cardiothoracic Surgery at the Hospital, is one ... this method, which involves making two microscopic incisions ...
Breaking Medicine Technology:An Introduction to Medical Device Software: Regulations and Requirements Course - London, UK - November 2-3, 2015 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 2Drug Delivery in Central Nervous System Diseases - Technologies, Markets and Companies Report 2015-2024 3Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 2Boca Regional Introduces Ultra-Minimally Invasive Surgical Procedure for Atrial Fibrillation Patients 3
... 2, 2010 CSA Medical, Inc. ( www.CSAmedical.com ) ... incoming president, CEO and member of the board of ... years of medical device experience, including market development roles ... "We are thrilled to have Bill join ...
... Dec. 2, 2010 Sagent Pharmaceuticals, Inc., a ... approval of four presentations of midazolam injection, USP, ... which will be offered in latex-free vials, in ... U.S. market for injectable midazolam approximated $52 million. ...
Cached Medicine Technology:CSA Medical Appoints William H. Floyd President and CEO 2Sagent Pharmaceuticals Announces FDA Approval of Midazolam Injection, USP 2
(Date:9/2/2015)... Athyn, PA (PRWEB) , ... September 02, 2015 , ... ... Heilman Hall at Bryn Athyn Church Elementary School, 600 Tomlinson Road, Bryn Athyn, Pa ... Inc., will host a day-long seminar featuring New York Times best-selling author Sam Keen ...
(Date:9/2/2015)... San Jose, CA (PRWEB) , ... September 02, ... ... connectivity for Internet of Things, announces its latest addition to its screen mirroring ... the existing award-winning Splashtop Extended Wireless Display, which operates in local WIFI setting, ...
(Date:9/2/2015)... ... September 02, 2015 , ... Michael Elliot Media announces ... a plus-size actress as the primary love interest in the film. The campaign is ... film, significantly affects how and what we think,” Michael Elliot, an award-winning screenwriter and ...
(Date:9/2/2015)... ... , ... Ericson is a noted speaker and educator in the field of ... Education for the Association for Clinical Documentation Improvement Specialists (ACDIS) where she developed and ... serves as a CDI subject matter expert for a variety of HCPro and ACDIS ...
(Date:9/2/2015)... ... September 02, 2015 , ... A recent survey by Consumer Reports ... year and its negative impact on consumers. It was reported that 33% are paying ... paying as much as an extra $100 compared to last year. Among the drugs ...
Breaking Medicine News(10 mins):Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 2Health News:Splashtop Launches Wired XDisplay, the Fastest Screen Sharing Solution for Extending and Mirroring Your Computer Screen to Mobile Devices 3Health News:Award-Winning Screenwriter Uses Crowdfunding Campaign to Change Hollywood’s Ideal of Beauty to Include PLUS-SIZE Women 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 2Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 3Health News:ezDI Names Noted CDI Educator Cheryl Ericson as Company’s Clinical Documentation Manager 4Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2
... data from a Phase 2 clinical trial of GVAX ... Johns Hopkins Sidney Kimmel Cancer Center. The trial ... GVAX after surgical resection of their tumor and adjuvant ... patients was previously reported to be 26.8 months, a ...
... end, even if it is all subtle, as in Canada ... pin down is more dangerous to mental health than ... living in Canada. ,"We found that the subtle ... such as symptoms of depression and anxiety," said lead author ...
... Annual Meeting of SNM, the world's largest society ... German researchers stated that early metabolic imaging with ... to chemotherapy for esophageal cancer. ,"This ... from early metabolic response assessment to clinical decision ...
... announced today that HHS has awarded a contract for $500 ... manufacture and deliver 20 million doses of a next generation ... would be recommended in the event of a smallpox outbreak ... immune systems. The full supply of the vaccine will be ...
... welcomed a new study to be published today in ... contribute to the steadily mounting evidence that undermines ... obesity. A report issued last Friday by the Federal ... Archives study found that "children do not currently see ...
... interim findings from its Phase II, multi-center clinical ... anthracycline currently in development for the treatment of ... indicate favorable interim results in terms of response ... current treatment standard, topotecan, in second-line treatment of ...
Cached Medicine News:Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 2Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 3Health News:Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer 4Health News:Koreans in Canada Feel Put Down by Subtle Racism 2Health News:Esophageal Cancer Patients' Positive Responses to Chemotherapy Accurately Identified by PET 2Health News:HHS Buys Next Generation Smallpox Vaccine 2Health News:HHS Buys Next Generation Smallpox Vaccine 3Health News:New Studies: Commercials Aren't Making Kids Fat 2Health News:Amrubicin Shows Encouraging Results for Small Cell Lung Cancer Treatment 2
Trial Lens Sets....
Magnets move the color disks, Protects Disks from fingerprints, Keeps all the disks in one place, Clear glass insures accurate color perception, Makes Color testing fun....
Solo-care is a multi-purpose solution for cleaning, rinsing, disinfection and storing soft contact lenses....
... Multi-Purpose Solution for cleaning, rinsing, disinfecting, ... loosens and removes accumulations of film, ... lenses. Destroys harmful micro-organisms on the ... and rewets lenses before insertion. Renu ...
Medicine Products: